How much funding has Continuity Biosciences raised?

Continuity Biosciences has raised $9.42M in total funding. Key investors include Boston Micro Fabrication.

Who is the CEO of Continuity Biosciences?

Ramakrishna Venugopalan is the CEO of Continuity Biosciences. The company was founded in 2024.

Where is Continuity Biosciences located?

Continuity Biosciences is headquartered in Bradenton, FL, USA.

What products does Continuity Biosciences offer?

Continuity Biosciences's key products include: ["Dissolvable microneedle patches"].

What funding stage is Continuity Biosciences at?

Continuity Biosciences is currently at the Active stage.

How many employees does Continuity Biosciences have?

Continuity Biosciences has approximately 1-10 employees.

Continuity Biosciences

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

MaterialsBradenton, FL, USAFounded 2024· One of 961 Materials companies tracked by AMPulse

Biofabrication platform for combination products using 3D microdispensing technology, founded by experts in translational medicine

CEO / Founder: Ramakrishna Venugopalan
Team Size: 1-10
Stage: Active
Total Funding: $9.42M
Latest Round: Venture Round
Key Investors: Boston Micro Fabrication

Technology & Products

Key Products

["Dissolvable microneedle patches"]

Technological Advantage

Strategic partnership with Boston Micro Fabrication, providing access to micro-precision printing technology.

Differentiation

Value Proposition

Enabling precise, potentially painless delivery of therapeutics and cosmetics via advanced dissolvable microneedles manufactured with high-resolution 3D printing.

How They Differentiate

Focus on ultra-high resolution 3D printing through a strategic collaboration with Boston Micro Fabrication, allowing for unique geometries not attainable with conventional manufacturing.

Market & Competition

Target Customers

Pharmaceutical and cosmetic companies

Industry Verticals

["Pharmaceuticals","Cosmetics"]

Competitors

Vaxxas; Raphas; Kindeva Drug Delivery

Growth & Milestones

Major Milestones

["Announced strategic investment and collaboration with Boston Micro Fabrication (May 2024)"]

Notable Customers

Breakthrough T1D; Houston Methodist Hospital; Miami School of Medicine

https://www.continuitybiosciences.com

Why this company matters

Continuity Biosciences is developing a biofabrication platform for combination products that combine drug or cosmetic formulations with advanced delivery mechanisms. The company focuses on dissolvable microneedle patches manufactured via ultra-high-resolution polymer 3D printing, aiming to enable precise, potentially painless delivery of therapeutics and cosmetics. This approach targets a gap in conventional microneedle manufacturing, which typically relies on molding or other methods that limit geometric complexity.

The core technology leverages microdispensing and micro-precision printing through a strategic partnership with Boston Micro Fabrication. This collaboration provides access to high-resolution additive manufacturing capable of producing complex microneedle geometries not achievable with traditional fabrication. The company has also licensed several technology platforms from Houston Methodist Hospital, including nanofluidic systems for drug delivery, cell storage systems for stem cell transplantation and immune modulation, the NICHE platform for Type 1 Diabetes, and an iontophoretic system for intratumoral delivery in oncology.

Target customers include pharmaceutical and cosmetic companies seeking innovative delivery solutions. Notable partners and customers include Breakthrough T1D, Houston Methodist Hospital, and Miami School of Medicine. The company serves the pharmaceuticals and cosmetics verticals, with applications ranging from vaccine delivery to skincare. Competitors include Vaxxas, Raphas, and Kindeva Drug Delivery, though Continuity differentiates through its focus on ultra-high-resolution 3D printing for unique microneedle geometries.

Founded in 2024 and based in Bradenton, FL, the company is led by CEO Ramakrishna Venugopalan, a former AbbVie senior executive specializing in drug delivery for products including Skyrizi. Continuity raised $9.42M in funding, with Boston Micro Fabrication as a key investor. The company announced a strategic investment and collaboration with Boston Micro Fabrication in May 2024. A key open question is whether its microdispensing platform can scale from pilot production to commercial volumes required by pharmaceutical and cosmetic partners.